SCHEMBL2108371

SCHEMBL2108371

CC(=O)N(C)c1cc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c(F)cc1F

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDKN1A P38936 1/20 0.48
KDM4E B2RXH2 4/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
KMT2A Q03164 1/20 0.37
RELA Q04206 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TLR8 Q9NR97 1/20 0.36
MAP2K1 Q02750 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
ALDH1A1 P00352 1/20 0.34
BRAF P15056 4/20 0.33
GSK3A P49840 2/20 0.33
EPHA2 P29317 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lorediplon SCHEMBL1316601 0.88 CDKN1A (0.54) CDKN1AKDM4ENPC1RAB9ASMN1; SMN2
Lorediplon SCHEMBL29376531 0.88 CDKN1A (0.54) CDKN1AKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL14632096 0.87 CDKN1A (0.49) CDKN1AKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2105416 0.84 CDKN1A (0.45) CDKN1AKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2107990 0.81 CDKN1A (0.55) CDKN1AKDM4ETLR8MAP2K1CLK4
SCHEMBL3241433 0.81 CDKN1A (0.54) CDKN1AKDM4ETLR8MAP2K1CLK4
SCHEMBL2108079 0.79 CDKN1A (0.53) CDKN1AKDM4ETLR8MAP2K1CLK4
Indiplon SCHEMBL30292630 0.79 CDKN1A (0.61) CDKN1AKDM4ETLR8MAP2K1CLK4
Indiplon SCHEMBL75094 0.79 CDKN1A (0.61) CDKN1AKDM4ETLR8MAP2K1CLK4
Indiplon SCHEMBL3714581 0.79 CDKN1A (0.61) CDKN1AKDM4ETLR8MAP2K1CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158632-B2 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2012-04-17 US claimed
EP-2059521-B1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2010-06-02 EP claimed
US-20090264448-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INTERNATIONAL, S.A. (ES) 2009-10-22 US claimed
EP-1884516-A1 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-06 EP claimed
US-8158632-B2 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2012-04-17 US disclosed
EP-2059521-B1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2010-06-02 EP disclosed
US-20090264448-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INTERNATIONAL, S.A. (ES) 2009-10-22 US disclosed
EP-1884516-A1 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264448-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS P2RX5, GABRA5, P2RX1 CDKN1A 1497/4885KDM4E 740/4885NPC1 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.